BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31888545)

  • 1. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
    Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
    BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
    Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
    Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β
    Baltes F; Pfeifer V; Silbermann K; Caspers J; Wantoch von Rekowski K; Schlesinger M; Bendas G
    Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118663. PubMed ID: 31987794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.
    Xu X; Liu J; Shen C; Ding L; Zhong F; Ouyang Y; Wang Y; He S
    Eur J Haematol; 2017 Jan; 98(1):4-12. PubMed ID: 26710889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
    Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
    Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
    Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.
    Liu J; Wang Y; He S; Xu X; Huang Y; Tang J; Wu Y; Miao X; He Y; Wang Q; Liang L; Cheng C
    Hematology; 2016 Dec; 21(10):603-612. PubMed ID: 27319807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
    Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
    Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.
    Fei M; Hang Q; Hou S; He S; Ruan C
    Mol Cell Biochem; 2014 Jan; 386(1-2):177-87. PubMed ID: 24170542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
    He Y; Wang Y; Liu H; Xu X; He S; Tang J; Huang Y; Miao X; Wu Y; Wang Q; Cheng C
    Leuk Res; 2015 Dec; 39(12):1428-36. PubMed ID: 26453405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.
    Shain KH; Yarde DN; Meads MB; Huang M; Jove R; Hazlehurst LA; Dalton WS
    Cancer Res; 2009 Feb; 69(3):1009-15. PubMed ID: 19155309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
    Hazlehurst LA; Damiano JS; Buyuksal I; Pledger WJ; Dalton WS
    Oncogene; 2000 Sep; 19(38):4319-27. PubMed ID: 10980607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
    Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
    Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
    Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
    Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
    Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.
    Fei M; Hang Q; Hou S; Ruan C
    Int J Hematol; 2013 Oct; 98(4):446-55. PubMed ID: 24037419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
    Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
    Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
    Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
    Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.